European Medicines Agency Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC Jun 22, 2022 Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review May 4, 2022 Novartis Nabs European Approval for Kymriah in Follicular Lymphoma Apr 22, 2022 EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation Oct 15, 2021 CHMP Recommends Gilead's Trodelvy for Pretreated TNBC Sep 17, 2021 CHMP Recommends Merck's Keytruda Plus Chemo for PD-L1-Positve TNBC Apr 23, 2021 European Commission Approves GSK's Dostarlimab in Endometrial Cancer Feb 16, 2021 AstraZeneca, Daiichi Sankyo's Enhertu Gets Conditional UK Approval in Metastatic Breast Cancer Dec 28, 2020 Janssen Seeks EU Approval for Amivantamab in Lung Cancer Sep 18, 2020 BMS's Opdivo, Yervoy Plus Chemo Gets Positive CHMP Opinion in NSCLC Regardless of PD-L1 Status Mar 31, 2020 Takeda's Adcetris Plus Chemotherapy Garners Positive CHMP Opinion in CD30-Positive sALCL Sep 20, 2019 Astellas Pharma Acute Myeloid Leukemia Drug Gets Positive CHMP Opinion Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
